Clinical Trials at Connecticut Retina Consultants
Reach out to us to find out more about our ongoing clinical trials.
For non-urgent issues, please send us your inquiries here. Please allow us 24-48 hours to get back to you. For urgent matters please contact our office.
If you would like more information or are interested in our clinical trials please contact Marilyn, Study Coordinator at (203) 365-6565.
Alcon Research – 2015 to 2018 – RTH Solution for Intravitreal Injection
Neovascular AMD
Rth258-C001
Chiltren – (2016 to 2017) – Squalamine Lactate Ophthalmic Solution
Neovasular AMD
OHR-1601
Opthotech – 2013 to 2016 – Fovista
Choroidal neovascularization secondary to AMD
OPH1002-AMD
Xoma Eye Guard – 2013 to 2015 – Gevokizumab
Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
XO52130/CL3-78989-005
XO52131/CL3-78989-006
X052132 – Rollover
Lux Biosciences 2011-2011 – Luminate
Treatment of Intermediate and Posterior Non-Infectious Uveitis
Alcon Pharmaceuticals 2010-2011 – Durezol vs Pred Forte
Treatment for Anterior Uveitis
1034 Phase III
Regeneron Pharmaceuticals 2008 – 2013 – Eylea
Neovascular AMD
VGTF-OD-0605 / View
VGTF-OD 0910
Allergan Pharmaceuticals 2006 – 2014 – Dexanmethasone
DME 206207-011
DME 206207-012
RVO 203207-009
Brimonidine GA 190342-032D
Genentech Pharmaceuticals 2004- 2013 – Lucentis
FVF4168g Ride Phase III – DME
FVF3192g Pier – AMD
FVF3689g Sailor – AMD
Eyetech Pharmaceuticals 2002- 2008 – Macugen
EOP 1003- AMD
EOP1006 – AMD
EOP1010 – AMD
EOP 1023 – DME
